We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sekisui has invested £14.4 million ($18.93 million) in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022.